相关实验视频

Updated: Sep 16, 2025

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

微RNA-21:在肺癌中是一种潜在的治疗点 (评论)

Zhouqiang Li¹, Hualing Zhang¹, Zeshan Chen²

¹Second Ward, Department of Respiratory and Critical Care Medicine, Liuzhou Hospital of Traditional Chinese Medicine, Liuzhou, Guangxi 545000, P.R. China.

International journal of oncology

|July 11, 2025

概括

微RNA-21 (miRNA-21) 通过影响关键路径和生物过程,驱动肺癌的进展. 抑制miRNA-21提供了一个有前途的治疗策略和肺癌的诊断生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

肺癌仍然是全球癌症相关死亡的主要原因.
微RNA-21 (miRNA-21) 已成为包括肺癌在内的各种癌症中的重要瘤基因.
了解miRNA-21的调节机制和下游影响对于开发有效的肺癌疗法至关重要.

研究的目的:

审查miRNA-21作为肺癌瘤基因的多方面的作用.
在肺癌进展中阐明miRNA-21调节的信号通路和生物过程.
探索针对miRNA-21.1.的治疗策略和诊断应用.

主要方法:

关于研究肺癌中miRNA-21的综合文献综述.
分析miRNA-21的调节机制,包括上游调节器和下游目标.
检查miRNA-21在关键信号通路 (PI3K/AKT,MEK/ERK,TGF-β/SMAD,Hippo,NF-κB,STAT3) 中的参与.
针对miRNA-21的治疗方法的审查,包括CRISPR/Cas9,天然剂,寡核酸,miRNA海绵和纳米输送系统.
评估miRNA-21作为诊断,预后和治疗反应的生物标志物的潜力.

主要成果:

miRNA-21通过向下游基因和调节增殖,入侵,转移,亡和血管生成来促进肺癌的进展.
它的表达是由转录因子,DNA甲基化和竞争性内源RNAs调节的.
较高的miRNA-21表达与耐化疗,放射治疗和免疫治疗的耐药性相关.
已经开发出各种抑制miRNA-21的方法,包括CRISPR/Cas9技术和miRNA海绵.
纳米传递系统增强了miRNA-21抑制剂的疗效.

结论:

miRNA-21是肺癌中关键的瘤基因,通过多个信号通路驱动瘤的进展.
准miRNA-21及其相关途径为肺癌提供了一个新的治疗策略.
miRNA-21具有作为肺癌诊断,预后和预测治疗反应的生物标志物的巨大潜力.
在miRNA-21抑制剂的进步及其临床试验应用为肺癌患者提供了新的希望.

关键词:

生物标志物生物标志物化疗化疗是一种化学疗法.肺癌是一种肺癌.这就是miRNA-2121的原因.它们的扩散和扩散.目标目标目标目标目标目标目标.

更多相关视频

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...